8-K: SIGA Technologies Reports Strong 2024 Financial Results Driven by TPOXX Sales

SIGA Technologies announces positive financial results for 2024, highlighted by increased product sales and significant pre-tax operating income.

Summary

• SIGA Technologies reported its financial results for the three and twelve months ended December 31, 2024.
• The company achieved $133 million in product sales for the year, marking the second consecutive year of revenue growth.
• Pre-tax operating income for 2024 was $70 million, and net income reached $59 million.
• Approximately $100 million of product sales were from oral and IV TPOXX to the U.S. Strategic National Stockpile (SNS).
• International sales contributed approximately $23 million to the total product sales.
• The company has procurement orders for oral TPOXX from 30 countries over the past three years.
• In January 2025, TPOXX received regulatory approval in Japan for the treatment of smallpox, mpox, cowpox, and complications following smallpox vaccination.

Sentiment

Score: 6

Explanation: While the company reports strong product sales and profitability, there is a decrease in operating income and net income compared to the previous year. The company also faces several risks related to government contracts and market conditions.

Positives

• Product sales increased to $133 million in 2024, demonstrating strong demand for SIGA's products.
• The company generated a pre-tax operating income of $70 million and a net income of $59 million in 2024, indicating profitability.
• SIGA has a diverse revenue base, with international sales to 13 countries in 2024 and procurement orders from 30 countries over the past three years.
• TPOXX received regulatory approval in Japan, expanding its market reach.
• The company has approximately $70 million of outstanding procurement orders, providing a solid foundation for future revenue.

Negatives

• Product sales for the three months ended December 31, 2024, were $79.8 million, lower than the $115.7 million reported for the same period in 2023.
• Operating income for the year ended December 31, 2024, was $70.0 million, lower than the $83.6 million reported for the same period in 2023.
• Net income for the year ended December 31, 2024, was $59.2 million, lower than the $68.1 million reported for the same period in 2023.

Risks

• The company's future performance is subject to various risks and uncertainties, including the risk that BARDA may not exercise all remaining options under the BARDA Contract.
• There is a risk that SIGA may not complete performance under the BARDA Contract on schedule or in accordance with contractual terms.
• The company faces the risk that the international biodefense market may not develop to a degree that allows SIGA to continue to successfully market TPOXX internationally.
• There are risks associated with potential delays in the delivery of products to customers due to the actions of contract manufacturing organizations or other vendors within the supply chain.
• The company's business is subject to the volatile and competitive nature of the biotechnology industry.

Future Outlook

SIGA remains focused on durable growth and impact, supported by approximately $70 million of outstanding procurement orders.

Management Comments

• Diem Nguyen, Chief Executive Officer, stated that 2024 was a year of strong financial performance and operational execution for SIGA.
• Diem Nguyen noted that the results mark the second consecutive year of product revenue growth, reflecting SIGA's continued financial strength.

Industry Context

SIGA's focus on orthopoxviruses and its flagship product TPOXX positions it as a key player in the global health sector, particularly in the development of countermeasures against infectious diseases.

Comparison to Industry Standards

• It's difficult to directly compare SIGA's performance to industry standards without knowing the specific peer group.
• However, companies like Chimerix, which also focuses on antiviral treatments, could be considered a comparable, though Chimerix has a broader portfolio.
• SIGA's reliance on government contracts is a common characteristic among biodefense companies, such as Emergent BioSolutions, but the specific contract terms and revenue recognition methods can vary significantly.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and future growth prospects.
• Employees are affected by the company's operational execution and financial stability.
• Customers, including government agencies, rely on SIGA's products to address global health threats.

Next Steps

• SIGA will host a conference call and webcast to provide a business update on March 11, 2025, at 4:30 P.M. ET.

Key Dates